Where does BioCryst Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), BioCryst Pharmaceuticals, Inc. ranks #7,242 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does BioCryst Pharmaceuticals, Inc. hold?

BioCryst Pharmaceuticals, Inc. holds 45 US utility patents granted between 2016 and 2025, spanning 9 technology areas.

What is BioCryst Pharmaceuticals, Inc.'s Innovation Score?

BioCryst Pharmaceuticals, Inc. has an Innovation Score of 43.5 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does BioCryst Pharmaceuticals, Inc. focus on?

BioCryst Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 45 patents, ranking #401 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is BioCryst Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

BioCryst Pharmaceuticals, Inc.'s recent grant velocity is +240% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for BioCryst Pharmaceuticals, Inc.'s patents?

BioCryst Pharmaceuticals, Inc.'s patents average 21.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the BioCryst Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

BioCryst Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 45 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Biocryst ranks #7,242 of 49,997 tracked US assignees by granted-patent volume, with 45 patents across 9 technology areas.

#7,242
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.5/100): 21.8
avg claims per patent: +240%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7242 · US Corporation #7,242 · 45 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 45 grants
UPPER-Q #7,242/49,997
PHOTO-FINISH Baltimore Aircoil
CPC-NARROW A61P · 9 areas
INNOV-PAR 43.5/100
CLAIMS-DENSE 21.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +240% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Baltimore Aircoil Company, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Biocryst’s 43.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.2 pts (30%) Velocity 6.7 pts (15%) Breadth 10.6 pts (24%) Claim depth 13.1 pts (30%)

Qualcomm Incorporated · highest

85
BioCryst Pharmaceuti… · this assignee

44
Eaton Cummins… · near

44
IXI Technology… · near

44
Memory · near

44
Delta Int'l… · near

44
3D Lighting… · lowest

7

What this shows Biocryst's Innovation Score is 43.5/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Biocryst?

Each dot is one of Biocryst’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biocryst’s own 21.8 claims/patent is ABOVE the 16.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Biocryst vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Biocryst's grants concentrate

BioCryst Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (9 grants) versus a trough of 2 in 2016. By volume, Biocryst sits between BVW Holding AG and CDW LLC.

Biocryst's three-year grant acceleration

BioCryst Pharmaceuticals, Inc. shows 19 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

BVW Holding

45
Baltimore Aircoil

45
Bandwidth

45
Beijing Wodong Ti…

45
Bloomberg Finance

45
Blue Evolution

45
California Expand…

45
CDW

45
Biocryst Pharmace… ◀

45

What this shows BioCryst holds 45 patents at rank #7,243, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near BioCryst

By rank, the assignees closest to #7,243 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in BioCryst's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for BioCryst, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), BioCryst ranks #401 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Memory Technologies LLC 44 Eaton Cummins Automated Transmission Technologies LLC 44 IXI Technology Holdings, Inc. 44 Delta Electronics Int'l (Singapore) Pte Ltd 44

Biocryst's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

BioCryst Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	4.4%
2017	2	4.4%
2018	2	4.4%
2019	4	8.9%
2020	6	13.3%
2021	9	20.0%
2022	3	6.7%
2023	9	20.0%
2024	7	15.6%
2025partial year	1	2.2%

Which technologies does BioCryst Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 45

C07D - Heterocyclic Compounds 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

Y02A - Technologies FOR Adaptation TO Climate Change 11

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 4

C07K - Peptides 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

BioCryst Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

BioCryst Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #7,242 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare BioCryst Pharmaceuticals, Inc. against BVW Holding AG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.